Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
Status:
Not yet recruiting
Trial end date:
2024-12-03
Target enrollment:
Participant gender:
Summary
Oncolytic viruses can selectively replicate in and destroy tumor cells. Recent studies
indicate that recombinant human adenovirus type 5 (H101), which is the first approved
oncolytic virus drug in the world, shows anti-tumor effects on liver cancer. This study aims
to further verify the effect and safety of recombinant human adenovirus type 5 combined with
HAIC in the treatment of intrahepatic mass-forming cholangiocarcinoma.